NovaGold Resources Inc. (NYSE:NG) Q1 2025 Earnings Conference Call April 1, 2025 11:00 AM ET Company Participants Melanie Hennessey - VP, Corporate Communications Greg Lang - President and CEO Peter Adamek - VP and CFO Conference Call Participants Fedor Shabalin - B. Riley Rabi Nizami - National Bank Financial Operator Thank you for standing by. This is the conference operator. Welcome to the NovaGold Resources Inc. First Quarter 2025 Financial Results Conference Call and Webcast. As a reminder, all partici ...

Financial Data and Key Metrics Changes - Q4 net sales were $340.4 million, down from $370.4 million in the prior year, with a decline of 0.9% when adjusted for the 53rd week [34][35] - Q4 adjusted EBITDA increased to $14.6 million from $5.3 million in the previous year, representing a nearly 300% increase in profitability [43] - Gross margin improved to 30.4% from 26.8% in the prior year, a 360 basis point increase [39] - Net loss for Q4 was $8.7 million, unchanged from the previous year, but adjusted net income improved to $1.6 million from an adjusted net loss of $7.5 million [41][42] - Full year 2024 sales were approximately $1.2 billion, with adjusted EPS of negative 53 cents per diluted share [44] Business Line Data and Key Metrics Changes - Fishing department sales increased by 10.3% in Q4, while camping sales rose by 5.2% [36] - Firearms unit sales increased mid-single digits, despite a 1.7% decline in the hunting and shooting sports department [38] - E-commerce sales were up double digits in Q4, contributing to over 17% of overall business [16][101] Market Data and Key Metrics Changes - Adjusted NICS data showed a 4.5% decline, but the company outperformed this with mid-single digit growth in firearm unit sales [13] - The company noted a trade down to lower-priced firearms, impacting sales dollars but maintaining average order value [39][74] Company Strategy and Development Direction - The company is focused on a transformation strategy aimed at improving omnichannel retail fundamentals and inventory efficiency [7][10] - Plans for 2025 include returning to same-store sales growth, improving gross margins, and paying down debt [17][49] - Four strategic initiatives for 2025 include focusing on core hunting and fishing products, leveraging local connections, enhancing personal protection offerings, and strengthening brand awareness [20][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the turnaround strategy, noting steady improvement in sales trends and inventory management [12][33] - The company anticipates challenges in Q1 due to calendar shifts but expects significant opportunities in Q2 and Q3 [61][62] - Management highlighted the importance of being prepared for seasonal demands and improving inventory flow [66][67] Other Important Information - The company ended the year with liquidity of $131 million, an increase of $40 million compared to the previous year [12][48] - Capital expenditures for 2024 were approximately $14.6 million, primarily for store maintenance and technology investments [48] Q&A Session Summary Question: Trends in sales for February and March - Management noted positive sales trends in February, with a shift in holiday timing affecting March sales [56][62] Question: Trade down environment and market share - Management indicated that the trade down in firearms could present an opportunity for market share gains, as they focus on stocking the right products [72][74] Question: Impact of tariffs on consumer behavior - Management stated that there has been no significant change in consumer behavior due to tariffs, attributing any sales shifts to timing of advertising [81][82] Question: Free cash flow conversion from EBITDA - Management expressed confidence in generating positive free cash flow through improved inventory efficiency and sales growth [63][116] Question: Store openings and portfolio optimization - Management confirmed plans for one new store opening and mentioned ongoing evaluations of underperforming stores [110][112]

Financial Data and Key Metrics Changes - In 2024, the company recorded revenue of $3.3 million from an optional license agreement with MSD, with expectations for future income from this agreement [44] - The net loss for 2024 was $10.6 million, an improvement from a loss of $22 million in 2023, driven by increased revenue and reduced R&D and G&A expenses [48][49] - Cash and cash equivalents at the end of December 2024 were $6 million, up from $5.6 million at the end of 2023, with sufficient funds projected to last into mid-2026 [46][51] Business Line Data and Key Metrics Changes - The ongoing EBX01 Phase II trial showed a 69% overall response rate at the one-year readout, with 15 out of 16 patients showing a reduction in tumor target lesions [8] - The company has established a new precision cancer vaccine concept targeting non-conventional endogenous retroviruses, broadening the potential of cancer vaccines [9][10] Market Data and Key Metrics Changes - The partnership with MSD, established in September 2024, is expected to lead to potential option exercises in the second half of 2025, which could generate up to $10 million in income [6][15] - The company aims to generate at least two new agreements in 2025, focusing on a multi-partner approach to expand its pipeline [17][18] Company Strategy and Development Direction - The company is focused on deriving value from both its platform and pipeline, emphasizing the complementarity of its AI immunology capabilities [18][20] - The strategy includes entering into high-value, low-risk partnerships for target discovery and the development of novel vaccine candidates [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong position, highlighting the successful execution of the pipeline and the transformative agreement with MSD [55][56] - The company is well-positioned for strong execution in 2025, with key milestones and value triggers locked in [56] Other Important Information - The company extended the EVX01 trial from two to three years to collect three-year outcome data, which is expected to enhance the data package for the personalized cancer vaccine [27] - The company has raised $17 million through public offerings and other capital market activities, extending its cash runway to mid-2026 [12][21] Q&A Session Summary Question: How does the company ensure new pipeline candidates are partnerable assets? - The company emphasizes unmet medical needs and commercial potential as primary criteria, engaging in early dialogues with potential partners to shape preclinical programs accordingly [62][64] Question: What data should be expected at the AACR regarding EBX01? - The company will present biomarker data and additional T cell data, providing a more in-depth analysis of the ongoing trial [80] Question: What types of cancers could the ERV vaccines target? - The company has identified specific cancer indications with a high burden where ERV sequences are shared across patients, with further information expected by the end of the year [86] Question: Will any data be released ahead of submitting to MSD for EVX B2 and B3? - No additional data will be released for B2, as MSD is conducting confirmatory work on existing data, while B3 is in the finalization stage of the work plan [89]

ASP Isotopes (ASPI) Q4 2024 Earnings Call April 01, 2025 02:52 PM ET Company Participants Nick Lawson - CEOPaul Mann - Chairman & CEOHendrik Strydom - CTO Nick Lawson Good morning, good afternoon, and good evening to wherever you are in the world. My name is Nick Lawson. I'm the CEO of OceanWall, and I'm delighted to welcome you to the ASP Isotopes fiscal year two thousand and twenty four results webinar. We're delighted to have with us Paul Mann, chairman and CEO, and doctor Henrik Streidom, who's ASPI's c ...

Financial Data and Key Metrics Changes - For fiscal year 2024, the company generated 110,652 certified loans, $24 million in revenue, and adjusted EBITDA of negative $42.9 million, largely due to fourth quarter results and the impact of a negative change in estimate [10][41] - Total revenue for Q4 2024 was negative $56.9 million, which includes a negative change in estimate of $81.3 million associated with profit share revenue [36][39] - Net loss for Q4 2024 was $144.4 million, compared to a net loss of $4.8 million in Q4 2023, with net loss per share at $1.21 compared to a net loss of $0.04 per share in the prior year [39][40] Business Line Data and Key Metrics Changes - The company facilitated 26,065 certified loans in Q4 2024, a slight decrease from 26,263 certified loans in Q4 2023 [35] - Profit share revenue in Q4 2024 associated with new originations was $8.2 million or $314 per certified loan, compared to $13.2 million or $501 per certified loan in Q4 2023 [38] Market Data and Key Metrics Changes - The Mannheim Used Vehicle Value Index (MOVIE) declined from 257.7% in late 2021 to 204.1% as of February 2025, representing a more than 20% decline in used vehicle values over the past three to four years [12][13] - The company observed an increase in 60-plus day delinquencies in Q4 2024, particularly from the 2021 and 2022 vintages [14] Company Strategy and Development Direction - The company is focused on strategic efforts to drive new customer acquisitions and certified loan growth while optimizing profitability for lenders and insurance partners [6][25] - Management plans to implement a sophisticated, segmented, and real-time data-driven pricing model to enhance predictability of profit share revenue [33][34] - The company aims to reduce the mix of borrowers with credit builder trade lines from approximately 15% in fiscal 2024 to under 5% in fiscal 2025 [23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging macroeconomic environment and the need for credit tightening and pricing adjustments to drive revenue [42] - The outlook for Q1 2025 expects total certified loans to be between 27,000 and 28,000, indicating a sequential increase from Q4 2024 [26] Other Important Information - The company announced a leadership change, with Jessica Buss becoming the new CEO, focusing on profitable unit economics and growth [27][30] - The company has signed 58 new customers in 2024 for its Lenders Protection Program, indicating strong market interest [25] Q&A Session Summary Question: Overview of Open Lending's situation from an insurance perspective - Management emphasized the need for a more insurance-like approach to pricing and operations to enhance profitability and reduce volatility [52][53] Question: Infrastructure and investment needed for changes - Management indicated that existing infrastructure is adequate, but improvements in data collection and predictive modeling are necessary [60][63] Question: Impact of credit builder trade lines on addressable market - Management noted that credit builder trade lines represented a small portion of the business and corrective actions have been taken to minimize their impact [78] Question: Insurance carriers' capacity and profitability - Management confirmed that insurance carriers have ample capacity to support future growth and that their long-term profitability remains strong [90][102] Question: Profit share per certified loan and future expectations - Management indicated that the current profit share per certified loan is constrained at around $300, with expectations to return to historical levels as performance improves [104][106] Question: Effects of tariffs on used car prices and affordability - Management noted that tariffs could positively impact the back book by increasing collateral prices but acknowledged the need for careful pricing adjustments to avoid future volatility [109]

BiomX (PHGE) Q4 2024 Earnings Call April 01, 2025 12:22 PM ET Company Participants Marina Wolfson - CFO & SecretaryJonathan Eitan Solomon - CEO and Board MemberJoe Pantginis - Managing Director Conference Call Participants Yale Jen - Senior Managing Director & Senior Biotech Analyst Operator Greetings, and welcome to today's BioMx Investor Presentation. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference ...

Flexible Solutions International Inc. (FSI) Q4 2024 Earnings Conference Call April 01, 2025 11:00 AM ET Company Participants Jen - Conference Call ModeratorDan O'Brien - CEO, Flexible Solutions International Conference Call Participants Tim Clarkson - Analyst, Van Clemens and Company Jen Good day, everyone, and welcome to today's Flexible Solutions International full-year 2024 financials conference call. At this time, all participants are in a listen-only mode. Later, you'll have the opportunity to ask ques ...

Financial Data and Key Metrics Changes - Gold sales totaled approximately 9,050 ounces for the fourth quarter and 21,500 ounces for the year, reflecting the impact of water issues at Granite Creek [38] - Total revenue from gold and silver sales was approximately $23 million for the fourth quarter and $50 million for the full year, slightly lower than the prior year due to lower volumes sold, partially offset by a higher average realized gold price [39] - The company concluded both the quarter and the full year in a net loss position due to ongoing development of projects, with growth expenditures primarily allocated towards infill drilling and pre-development activities [40] Business Line Data and Key Metrics Changes - At Granite Creek Underground, approximately 38,000 ounces of gold were mined, achieving 71% of the internal target, with production just above 16,000 ounces [20] - Production from heap leach operations exceeded internal targets, with approximately 6,200 ounces produced from Lone Tree and 3,700 ounces from Ruby Hill [24] - The company expects to produce between 30,000 and 40,000 ounces of gold in 2025, with Granite Creek Underground contributing 20,000 to 30,000 ounces [25] Market Data and Key Metrics Changes - The company filed four SK 1300s and four NI 43-101 reports under US and Canadian regulations, respectively, highlighting the potential value of its gold portfolio [7][8] - Life of mine valuations based on recent published PAs indicate a combined net present value of $1.6 billion at a gold price of $2,175 per ounce and $4.5 billion at $2,900 per ounce [11] Company Strategy and Development Direction - The company announced a new development plan for its portfolio of three underground and two open pit gold projects, aiming to produce half a million ounces of gold by the early 2030s [4][9] - A strategic change to the development plan includes the addition of the autoclave refurbishment, which is pivotal for the recapitalization plan [12][14] - The company is in active discussions regarding financing options, including a senior debt facility and royalty sales, to support its development plan [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the activities being manageable and staggered, with expectations for improved cash flow models as feasibility studies are released [10] - The anticipated capital spend for the autoclave refurbishment is included in the recapitalization plan, with a goal to secure new senior financing by the second quarter of 2026 [17] - Management highlighted the importance of advancing permitting activities and investing in feasibility studies as top priorities for growth expenditures [46] Other Important Information - The company transitioned from IFRS to US GAAP as of January 1, 2025, impacting the reporting of pre-development costs and resulting in several financial adjustments [34][36] - The company has maintained a clean environmental record, ending the fourth consecutive year without any environmental violation notices [19] Q&A Session Summary Question: What is the status of the recapitalization plan? - Management indicated that the recapitalization plan is well underway, with agreements in place with National Bank and Aramet, reflecting confidence in the quality of the technical reports filed [51]

AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Conference Call April 01, 2025 08:30 AM ET Company Participants Conference Call Operator - Operator/Introductory AnnouncerThomas Echols - Chief Executive OfficerConference Call Operator - Q&A Moderator Conference Call Participants Ed Wu - Analyst at Ascendant Capital Markets Conference Call Operator Hello and welcome to the AIM Immunotech fourth quarter and full year 2024 update conference call and webcast. As a brief reminder, all participants are currently in a l ...

Financial Data and Key Metrics Changes - The company achieved record annual revenue of $380 million, a 24% increase year-over-year, with fourth quarter revenue reaching $113.4 million, reflecting a strong growth margin of 36.6% [11][28] - Gross profit for Q4 2024 was $41.5 million, an 80% improvement from $23 million in Q4 2023, resulting in a gross margin of 36.6%, up from 22% in the prior year [28][29] - The adjusted EBITDA for Q4 2024 was $8.6 million, compared to a negative $2.6 million in the prior year period, indicating effective strategic execution [35] Business Line Data and Key Metrics Changes - The company reported a significant increase in backlog, growing to $401.3 million, driven by regional demand for technology [19] - The ME6 energy storage system and advancements in silicon-based cell technologies were highlighted as key product innovations [10][18] Market Data and Key Metrics Changes - In the EMEA region, revenue grew by 123% year-over-year to $187.7 million, accounting for nearly half of total revenue [37] - The U.S. market saw a 360% increase in revenue, rising from $3.1 million in 2023 to $14.4 million in 2024, reflecting early adoption by commercial vehicle OEMs [38] - Revenue in the Asia Pacific region declined by 19% year-over-year, from $219.1 million in 2023 to $177.7 million in 2024, due to strategic repositioning away from low-margin segments [39] Company Strategy and Development Direction - The company is focused on improving efficiency and profitability, with a goal of becoming cash flow positive and maintaining strong gross margins while expanding to meet customer demand [15][44] - The Huzhou State 3.2% expansion project is expected to add up to 2 gigawatt hours of production capacity, anticipated to come online in Q1 2025 [16][45] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to continue as a going concern, citing improved operating results and stronger cash positioning [36] - The revenue guidance for 2025 is projected to increase by 18% to 25%, with a target range of $450 million to $475 million [44][46] Other Important Information - The company faced challenges in 2024, including a difficult financing environment and supply constraints, but responded with strategic cost control and operational adjustments [22][48] - The company has made substantial strides in technology innovation, including the unveiling of the ME6 Energy Storage System and advancements in battery technologies [48] Q&A Session Summary Question: What are the expectations for revenue growth in 2025? - The company expects revenue to increase by 18% to 25% year-over-year, with a target range of $450 million to $475 million [44] Question: How is the company addressing challenges in the APAC region? - The company is strategically repositioning away from low-margin segments in China and India, focusing on more profitable opportunities [39] Question: What is the outlook for the EMEA market? - The EMEA market is expected to continue driving significant revenue increases year-over-year, supported by strong commercial traction [46]